Cargando…
Developments in Diagnosis and Antileishmanial Drugs
Leishmaniasis ranks the third in disease burden in disability-adjusted life years caused by neglected tropical diseases and is the second cause of parasite-related deaths after malaria; but for a variety of reasons, it is not receiving the attention that would be justified seeing its importance. Lei...
Autores principales: | Bhargava, Prachi, Singh, Rajni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3483814/ https://www.ncbi.nlm.nih.gov/pubmed/23118748 http://dx.doi.org/10.1155/2012/626838 |
Ejemplares similares
-
Strategies to Overcome Antileishmanial Drugs Unresponsiveness
por: Sundar, Shyam, et al.
Publicado: (2014) -
Antileishmanial Drug Discovery and Development: Time to Reset the Model?
por: Olías-Molero, Ana Isabel, et al.
Publicado: (2021) -
Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs
por: Kip, Anke E., et al.
Publicado: (2017) -
The Potential of 2-Substituted Quinolines as Antileishmanial Drug Candidates
por: Loiseau, Philippe M., et al.
Publicado: (2022) -
Marine Algae as Source of Novel Antileishmanial Drugs: A Review
por: Tchokouaha Yamthe, Lauve Rachel, et al.
Publicado: (2017)